Cell-free DNA from cerebrospinal fluid can be used to detect the EGFR mutation status of lung adenocarcinoma patients with central nervous system metastasis
| Autor: | Qiming Wang, Xiaopeng Yang, Wei Wang, Arsela Prelaj, Jiuzhou Zhao, Nicola Normanno, Yongjun Guo, Zhen He, Jie Ma, Marcello Tiseo, Paul Van Schil, Yang Liu, Sen Yang, Akihiko Yoshizawa |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Cerebrospinal fluid (CSF) Liquid biopsy Leptomeningeal metastasis (LM) business.industry Hazard ratio non-small cell lung cancer (NSCLC) Non-small cell lung cancer (NSCLC) medicine.disease Gastroenterology Metastasis Cerebrospinal fluid Oncology Internal medicine Medicine Adenocarcinoma Human medicine EGFR mutation business Lung cancer Brain metastasis |
| Zdroj: | Translational lung cancer research |
| ISSN: | 2226-4477 2218-6751 |
| DOI: | 10.21037/tlcr-21-62 |
| Popis: | Background: EGFR tyrosine kinase inhibitors (TKIs) have revolutionized the therapeutic approach for EGFR mutated patients. However, acquired resistance to EGFR-TKI therapy is unavoidable. Repeat biopsy cannot be used, and peripheral blood detection shows a low positive rate in cases of brain-only disease progression. Methods: Droplet digital polymerase chain reaction (PCR) (ddPCR) was performed on the plasma and cerebrospinal fluid (CSF) samples of 79 lung adenocarcinoma (LUAD) patients with EGFR mutations and central nervous system (CNS) metastasis. The differences in the EGFR mutation status between the paired plasma and CSF samples were assessed, and the role of CSF testing as a predictor of overall survival was evaluated. Results: The CSF of patients with neurological symptoms, EGFR-TKI treatment, or leptomeningeal metastasis (LM) had a significantly higher positive rate of EGFR mutation compared to the plasma samples (P=0.001, P=0.035, P=0.019, respectively). Moreover, EGFR mutation status in CSF was consistent with neurological symptoms and LM (kappa =0.455, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|